| Year |
Citation |
Score |
| 2017 |
Zeineldin R, Syoufjy J. Cancer Nanotechnology: Opportunities for Prevention, Diagnosis, and Therapy. Methods of Molecular Biology. 1530: 3-12. PMID 28150193 DOI: 10.1007/978-1-4939-6646-2_1 |
0.31 |
|
| 2013 |
Youkhanna J, Syoufjy J, Rhorer M, Oladeinde O, Zeineldin R. Toward nanotechnology-based solutions for a particular disease: ovarian cancer as an example Nano Reviews. 2: 473-484. DOI: 10.1515/Ntrev-2013-0008 |
0.323 |
|
| 2012 |
Goncharov K, Zeineldin RR. Abstract 4227: Sensitizing resistant ovarian cancer to chemotherapy through inhibition of small GTPases Cancer Research. 72: 4227-4227. DOI: 10.1158/1538-7445.Am2012-4227 |
0.353 |
|
| 2012 |
Zeineldin R. Carbon Nanotubes for Targeted Cancer Therapy Nanotechnologies For the Life Sciences. DOI: 10.1002/9783527610419.Ntls0241 |
0.358 |
|
| 2011 |
Kim PS, Djazayeri S, Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecologic Oncology. 120: 393-403. PMID 21168905 DOI: 10.1016/J.Ygyno.2010.11.029 |
0.366 |
|
| 2011 |
Wandinger-Ness A, Kenney SR, Agola J, Roxby J, Surviladze Z, Silberberg M, Zeineldin R, Vestling A, Bologa C, Ursu O, Oprea T, Muller C, Lomo L, Sklar L, Hudson LG. Abstract LB-214: Rac1 and Cdc42 GTPases as novel targets in ovarian cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-214 |
0.652 |
|
| 2010 |
Zeineldin R, Ning Y, Hudson LG. The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 58: 529-41. PMID 20159766 DOI: 10.1369/Jhc.2010.955104 |
0.705 |
|
| 2010 |
Zeineldin R, Muller CY, Stack MS, Hudson LG. Targeting the EGF receptor for ovarian cancer therapy. Journal of Oncology. 2010: 414676. PMID 20066160 DOI: 10.1155/2010/414676 |
0.665 |
|
| 2009 |
Hudson LG, Zeineldin R, Silberberg M, Stack MS. Activated epidermal growth factor receptor in ovarian cancer. Cancer Treatment and Research. 149: 203-26. PMID 19763438 DOI: 10.1007/978-0-387-98094-2_10 |
0.649 |
|
| 2009 |
Zeineldin R, Al-Haik M, Hudson LG. Role of polyethylene glycol integrity in specific receptor targeting of carbon nanotubes to cancer cells. Nano Letters. 9: 751-7. PMID 19152309 DOI: 10.1021/Nl8033174 |
0.63 |
|
| 2008 |
Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clinical & Experimental Metastasis. 25: 643-55. PMID 18398687 DOI: 10.1007/S10585-008-9171-5 |
0.637 |
|
| 2007 |
Cowden Dahl KD, Zeineldin R, Hudson LG. PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Molecular Cancer Research : McR. 5: 413-21. PMID 17475671 DOI: 10.1158/1541-7786.Mcr-07-0019 |
0.637 |
|
| 2006 |
Zeineldin R, Rosenberg M, Ortega D, Buhr C, Chavez MG, Stack MS, Kusewitt DF, Hudson LG. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Molecular Carcinogenesis. 45: 851-60. PMID 16788982 DOI: 10.1002/Mc.20237 |
0.683 |
|
| 2006 |
Zeineldin R, Hudson LG. Epithelial cell migration in response to epidermal growth factor. Methods in Molecular Biology (Clifton, N.J.). 327: 147-58. PMID 16780219 DOI: 10.1385/1-59745-012-X:147 |
0.651 |
|
| 2005 |
Ning Y, Zeineldin R, Liu Y, Rosenberg M, Stack MS, Hudson LG. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Research. 65: 9280-6. PMID 16230389 DOI: 10.1158/0008-5472.Can-05-0407 |
0.727 |
|
| Show low-probability matches. |